Danaher Corporation is an American globally diversified conglomerate with its headquarters in Washington, D.C.. The company designs, manufactures, and markets professional, medical, industrial, and commercial products and services. The company's 3 platforms are Life Sciences, Diagnostics, and Environmental & Applied Solutions.
| Revenue (TTM) | $25.11B |
| Gross Profit (TTM) | $14.75B |
| EBITDA | $8.03B |
| Operating Margin | 19.80% |
| Return on Equity | 7.61% |
| Return on Assets | 3.95% |
| Revenue/Share (TTM) | $35.47 |
| Book Value | $74.82 |
| Price-to-Book | 2.63 |
| Price-to-Sales (TTM) | 5.57 |
| EV/Revenue | 6.39 |
| EV/EBITDA | 21.14 |
| Quarterly Earnings Growth (YoY) | 59.70% |
| Quarterly Revenue Growth (YoY) | 5.50% |
| Shares Outstanding | $702.99M |
| Float | $625.84M |
| % Insiders | 10.81% |
| % Institutions | 84.92% |
Volatility is currently expanding
The average of price targets set by Wall Street analysts indicates a potential upside of 32.4% in Danaher (DHR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
There's reason to believe the stock can stage a comeback after its worst day in two decades.
DHR beats Q2 estimates as Life Sciences posts its strongest quarter in years, prompting the company to raise its 2026 adjusted EPS outlook.
Danaher Corporation delivered Q2 revenue of $6.3B (+5.5% y/y), beating estimates and showing segment growth across Biotechnology, Diagnostics, and Life Sciences. Gross margins declined due to higher cost of sales, but operating margins improved significantly on tight SG&A control and DBS-driven productivity. Management raised full-year EPS guidance slightly, but projected low single-digit revenue growth and a slow recovery, disappointing investors and triggering a 14% share price drop.
Danaher Corporation (DHR) Q2 2026 Earnings Call Transcript
The headline numbers for Danaher (DHR) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Danaher NYSE: DHR reported better-than-expected second-quarter 2026 results, with management citing accelerating core revenue growth, stronger life sciences demand and benefits from productivity initiatives, while also addressing investor concerns over delayed bioprocessing shipments.
Stock futures are rising after three straight days of declines for major indexes; chip stocks are leading the rebound as volatility in the AI trade persists; several big-name companies reported earnings this morning ahead of Big Tech results tomorrow; Nebius shares are surging on news Nvidia as increased its stake in the Dutch AI infrastructure company; and SpaceX shares are rising after closing lower for the seventh consecutive sessions. Here's what you need to know today.
Danaher (DHR) came out with quarterly earnings of $1.94 per share, beating the Zacks Consensus Estimate of $1.84 per share. This compares to earnings of $1.8 per share a year ago.
WASHINGTON, July 21, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) today announced results for the second quarter 2026. All results in this release reflect only continuing operations and period-to-period comparisons are year-over-year unless otherwise noted.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on DHR and any ticker you trade — then tracks every position and per-strategy win rate.
